Delhi HC: Bipolar Disorder Alone Does Not Qualify as Medical Disability Without Benchmark Criteria || Kerala HC: Excommunicating Knanaya Catholics For Marrying Outside the Community is Unconstitutional || Kerala HC: Temporary Use of Religious Land For Public Infrastructure is Not a ‘Transfer’ under Law || P&H HC: Habeas Plea in Child Custody Case Not Maintainable if Child is With Natural Guardian and Safe || Delhi HC: Illegal Termination Does Not Automatically Entitle Employee to Reinstatement or Back Wages || Gujarat High Court: Forcing Toddler to Attend Court 6 Hours Weekly For Grandfather Visits is Unjust || Supreme Court Rejects Sameer Wankhede’s Plea, Directs Timely Resolution of Disciplinary Proceedings || Supreme Court Rejects NHAI Review on Solatium Retrospectivity, Bars Reopening Settled Claims || SC: Excise Duty Exemptions Based on Intended Use Must be Construed Liberally For Assessee || Supreme Court: DSC Personnel Eligible For Second Pension; Allows Condonation of Shortfall

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK MERCK PATENT DIABETES

Share :